Early ovarian cancer: A review of ITS genetic and biologic factors, detection, and treatment

Current Problems in Cancer

Volumn 20, Issue 2, 1996, Pages 86-137

  Boente, Matthew P ^a   Godwin, Andrew K ^a   Kohler, Matthew F ^b   Berchuck, Andrew ^c   Hamilton, Thomas C ^a   Buetow, Kenneth ^a   Michael Hogan, W ^a   Young, Robert C ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

FEMALE; GENETIC MARKER; GENETICS; HUMAN; INCIDENCE; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE;

COMBINED MODALITY THERAPY; FEMALE; GENETIC MARKERS; HUMANS; INCIDENCE; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 85045534410     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-0272(96)80005-5     Document Type: Note

References (156)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1993. CA Cancer J Clin 1993:43:75.
2. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993;71(suppl 4):1534-70.
3. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma, I: a patient care evaluation study of the American College of Surgeons. Cancer 1993:71:1629-38.
4. Roush GC, et al. Cancer risk and incidence trends: the Connecticut perspective New York: Hemisphere, 1987.
5. Buell P, Dünn JE. Cancer mortality among the Japanese Issei and Nisei of California. Cancer 1965:18:656.
6. Fathalla ME Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971;2:163.
7. Hartge P Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989;161:10.
8. Nasca PS, Greenwald P, Chorost S, et al. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984;119:205.
9. Booth M, Beral V, Smith P Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989:60:592.
10. Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 case-controlled studies. Am J Epidemiol 1992:136:1184.
11. Rossing MA. Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994:331:771-6.
12. Hanikson SE. Hunter DJ, Colditz GA, et al. Tuhal ligation, hysterectomy and risk of ovarian cancer: a prospective study. JAMA 1993:270:2813-8.
13. Weiss NS, Lyon JL, Lift JM, et al. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981:28:669.
14. Kerlikowske K, Brown JS, Grady DG, Should women with familial ovarian cancer undergo prophylactic oophoreclomy? Ohstet Gynecol 1991:80:700-7.
15. Gross TP, Schlesselman JJ, The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994:83:419-24.
16. Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982:247:3210.
17. Hamilton TC, Godwin AK, Salazar H, et al. Premalignant and early malignant ovarian neoplasms in prophylactic oophoreclomy specimens from women with a strong family history of ovarian cancer. Proc Am Soc Clin Oncol 1994:13:836.
18. Fox H. Pathology of early malignant change in the ovary. Int J Gynecol Pathol 1993:12:153-5.
19. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993:82:181-6.
20. Mittal KR. Zeleniuch-Jacquotte A. Cooper JL. Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993:12:59-63.
21. Murray JC. Huetow KH, Weber JL. et al. A comprehensive human linkage map with centimorgan density. Science 1994:265:2049-54.
22. Neuhausen SL. Swensen J. Miki Y. et al. A P-1 based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCAl. Human Molecular Genetics 1994:11:1919-26.
23. Miki Y, Swensen J, Shattuck-Eidens D. et al. A strong candidate for the breast and ovarian susceptibility gone BRCAl. Science 1994:266-71.
24. Knudson AC. Antioncogenes and human cancer. Proc Natl Acad Sci LI S A 1993:90:10914-21.
25. Knudson AC. All in the (cancer) family. Nature Genetics 1993:5:103-4
26. Berchuck A. Kamel A. Whitaker R. et al., et al. Overexpression of HER-21 neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990:40:4087-91.
27. Bellacosa A, deEeo D. Godwin AK. et ul.AKTS oncogene RNA overexpression, DNA amplification and rearrangement in ovarian and breast carcinomas. Submitted for publication. 1995.
28. Cheng JQ, Godwin AK. Bellacosa A. et al. AKT2. a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases. is amplified in human ovarian carcinomas. Proc Natl Acad Sei USA 1992:89:9267-71.
29. Lee JH, Kavanagh JJ. Wildrick DM. Wharton JT. Blick M. Frequent loss of hetero/ygosity on chromosomes 6q. 11 and 17 in human ovarian carcinomas. Cancer Res 1990:50:2724-8.
30. Zheng J. Robinson WR, Ehlen T, Yu MC. Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosome 3. 6. and 11 and Hi':n-2!neu gene amplification. Cancer Res 1991:51:4045-51.
31. Sato T. Saito 11. Morita R. Koi S. Lee JH. Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991:51:5118-22.
32. Saito S, Saito H, Koi S, et al. Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res 1992:52:5815-7.
33. Li S, Schwartz PE, Lee WH, Yang-Feng TL. Allele loss at the retinoblastoma locus in human ovarian cancer. Monogr Natl Cancer Inst 1991:83:637-40.
34. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimara T, Terada M, Yokota J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991:51:5171-6.
35. Godwin AK, Vanderveer L, Schultz DC, et al. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCAl. Am J Hum Genet 1994:55:666-77.
36. Yang-Feng TL, Han H, Chen KC, et al. Allelic loss in ovarian cancer. Int J Cancer 1993:54:546-51.
37. Jacobs IJ, Smith SA, Wiseman RW, et al. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 1993:53:1218-21.
38. Yang-Feng TL, Han H, Chen KC, et al. Allelic loss in ovarian cancer. Int J Cancer 1993:54:546-51.
39. Schultz DC, Wong A, Vanderveer L, Berman D, Hamilton TC, Godwin AK. Identification of a candidate tumor suppressor gene on chromosome 17pl3.3 and its role in the development of human ovarian adenocarcinoma. Submitted for publication, 1995.
40. Schultz DC, Vanderveer L, Buetow KH, Boente MR Ozols RF, Hamilton TC, Godwin AK. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2, Cancer Res [in press], 1995.
41. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
42. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM. Familial breast-ovarian cancer locus on chromosome 17ql2-q23. Lancet 1991:338:82-3.
43. Easton DF Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am f Hum Genet 1993:52:678-701.
44. Narod SA, Ford D, Devilee P, et al., and the Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 breast-cancer families. Am J Hum Genet 1995:56:254-64.
45. Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCAl locus on chromosome 17. Nature Genetics 1994:7:103-7.
46. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 -mutation carriers. Am J Hum Genet 1995:56:265-71.
47. Smith SA, Easton DF Evans DGR, Ponder BAI. Allele losses in the region 17ql2-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 1992;2:128-31.
48. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCAl mutations in primary breast and ovarian carcinomas. Science 1994:266:120-2
49. Simard J, Tonin R Durocher F et al. Common origins of BRCAl mutations in Canadian breast and ovarian cancer families. Nature Genetics 1994;8.
50. Castilla LH, Couch FJ, Erdos MR, et al. Mutations in the BRCAF1 gene in families with early-onset breast and ovarian cancer. Nature Genetics 1994:8:387-91.
51. Friedman LS, Ostermeyer EA. Szabo CI, Dowd R Lynch ED, Rowell SE, King MC. Confirmation of BRCAl by analysis of gernilino mutations linked to breast and ovarian cancer in ten families. Nature Genetics 1994;8:399-404.
52. Phillips N, Ziegler M, Saha B, Xynos E Allelic loss on chromosome 17 in human ovarian cancer. Int J Cancer 1993:54:85-91.
53. Saito H. InaJ.awa I, Saito S, et at. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 1993:53:3382-5.
54. Hosking L, Trowsdale J, Nicolai H, et al. A somatic BRCAl mutation in an ovarian tumour. Nature Genetics 1995;9.
55. Merajver SD, Pham TM, Caduff RE et al. Somatic mutations in the BRCAl gene in sporadic ovarian tumours. Nature Genetics 1995:9.
56. Buetow KH, McGlynn KA. Rosvold EA. et al. A candidate susceptibility locus for human ovarian carcinoma. Nature Genetics, submitted 1995.
57. Shatluck-Eidens D, McClure M, Simard J. et al. A collaborative survey of 80 mutations in the BRCAl breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995:273:7.
58. Wooster R, Neuhausen SL. Mangion J. et al. Localization of a breast cancer susceptibility gene, RHC/\2, to chromosome 13ql2-13. Science 1994;265:2088-90.
59. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequencespecific DNA-biuding protein. Science 1991:252:1708-11.
60. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993:74:817-25.
61. Eccles DM, Rüssel SEH, Haites NE, and the ABE Ovarian Genetics Group. Early loss of helerozygosity in ovarian cancer. Oncogene 1992:7:2069-72.
62. Foulkes WD, Black DM, Stamp GVVH. et al. Very frequent loss of hetero/ygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int I Cancer 1993:54:220-5.
63. Tavassoli M, Ruhrberg C, Beaumont V, Reynolds K, Kirkham N. Collins SR Farzaneh F. Whole chromosome 17 loss in ovarian cancer. Genes Chromosom Cancer 1993:8:195-8.
64. Foulkes W. Tumour suppressor genes in ovarian cancer. Br Med | 1993:307:1009.
65. Baker SF Markowitz S. Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990:249:912-5.
66. Nigro JM. Baker SJ, Preisinger AC. et al. Mutations in thep.T,'^ gene occur in diverse human tumour types. Nature 1989:342:705-8.
67. Hollstein M. Sidransky D. Vogelstein B. et al. p53 mutations in human cancers. Science 1991:253:49-53.
68. Davidolï AM, Humphrey PA, Iglehart [D, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sei L) S A 1991:88:5006-10.
69. Kohler MF Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992:52:1622-7.
70. Marks JR Jr, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991:51:2979-84.
71. Banks L. Matlashfiwski G. Crawford L. Isolation of human /w.'J-specif'ic monoclonal antibodies and their use in the studies of bumanp53 expression. Furl Biochem 1986:159:529-34.
72. Mazars K, Pujol R Maudelonde T. et al. po3 mutations in ovarian cancer: a late event. Oncogene 1991:6:1685-90.
73. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sei USA 1993;90:4961-5.
74. Kerns BJ, Jordon PA, Moore MB, et al. p53 overexpression in formalin-fixed, paraffin embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992:40:1047-51.
75. Kohler MF, Kerns BJ, Humphrey PA, et al. p53 overexpression and mutation in early stage epithelial ovarian cancer. Obstet Gynecol 1993:81:643-50.
76. Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-4.
77. Jacobs I, Kohler MF, Wiseman R, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and Xchromosome inactivation. Monogr Natl Cancer Inst 1992;84:1793-8.
78. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991:350:427-8.
79. Chiba I, Takahasshi T, Nau MM, et al. Mutations in thep53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990;5:1603-10.
80. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. Monogr Natl Cancer Inst 1993:85:1513-9.
81. Okamota A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991:51:5171-6.
82. Knudson AC Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sei USA 1971:68:820-3.
83. Malkin D, Li FR Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990:250:1233-8.
84. Harlap S. The epidemiology of ovarian cancer. In: Markman J, Hoskins WH, eds. Cancer of the ovary. New York: Raven Press, 1993:79-93.
85. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993:53:4129-33.
86. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244.
87. Leary JA, Edwards BG, Houghton CRS, Kefford RF, Friedlander ML. Amplification of HER-2/neu oncogene in human ovarian cancer. Int J Gynecol Cancer 1992:2:291-4.
88. Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Strickler JG. Activation of c-erbB-2 and prognosis in ovarian carcinoma: comparison with histologie type, grade and stage. Cancer 1994;73:1460-6.
89. Makar A, Holm R, Kristensen GB, Nesland JM, Trope CG. The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. Int J Gynecol Cancer 1994:4:194-9.
90. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-/MS proto-oncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993:53:1489-92.
91. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and KI-HAS gene mutations in epithelial ovarian neoplasms. Cancer Res 1993:53:3103-8.
92. Baker W, Morst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990:38:340-2.
93. Boente MR Godwin AK, Hogan WM. Screening, imaging and early diagnosis of ovarian cancer. Clin Obstet Gynecol 1994:37:377-91.
94. Hoentn MR Berchnck A, Bast RC Jr. Immunology of gynecologic cancers. In: Hoskins WJ. Ferez ÇA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: JB Lippincott, 1992:117-29.
95. Bast RC, Klug TL. St. John ER, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983:309:883.
96. Einhorn N, Sjovall K. Schoenfeld DA, el al. Early detection of ovarian cancer using the CA 125 radioimmunoassay (RIA). Proc Annu.
97. Jacobs I, Davies AR Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993:300:1030-4.
98. Jacobs IJ. Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAC 72.3. Obstet Gynecol 1992:80:396-9.
99. Xu FJ, Ramakrishnan S, Daly L, et al. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991:165:1356-62.
100. Xu FJ, Yu YA, Daly L, et al. The OVX1 radioimmunoassay complements CA125 for predicting the presence of residual ovarian carcinoma at secondlook surgical surveillance procedures. J Clin Oncol 1993:11:1506-10.
101. Woolas RR Xu FJ, Jacobs IJ, et al. Elevations of multiple serum markers in patients with stage I ovarian cancer. Monogr Natl Cancer Inst 1993:85:1748.
102. Granberg A, Norstrom A, Wikland M. Comparison of endovaginal ultrasound and cytological evaluation of cystic ovarian tumors. Ultrasound Med Biol 1991:10:9-14.
103. Movie JW, Rocliester D, Sider L, et al. Sonography of ovarian tumors: predictability of tumor type. AJR Am J Roentgenol 1983:141:985-91.
104. Granberg S, Crona N, Enk L, et al. Ultrasound guided puncture of cystic tumors in the lower pelvis of young women. JCl) J (Hin Ultrasound 1989:17:107-11.
105. Requard CK, Mettler FA, Wicks JD. Preoperative sonography of malignant ovarian neoplasms. AJR 1981:137:79-82.
106. Meire HB, Farrant R Cuba T Distinction of benign from malignant ovarian cysts by ultrasound. Br J Obstet Gynaecol 1978:85:893-9.
107. Lerner JR Timor-Tritsch IE, Federman A. Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994:170:81-5.
108. Woiner Z, Thaler I, Beck D. et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992:79:159.
109. Bourne T, Campbell S. Steer C, Whitehead MI, Collins WR Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ 1989:299:1367.
110. Hata T, Hâta K. Senoh D. et al. Doppler ultrasound assessment of tumor vascularity in gynecologic disorders. Ultrasound Med 1989:8:309-14.
111. Kuwai M. Kano T, Kikkawa F, Maeda O, Oguchi H, Toinoda Y. Transvaginal Doppler ultrasound with color How imaging in the diagnosis of ovarian cancer. Obstet Gynecol 1992:79:163-7.
112. Kurjak A, Zalud I, Jurkovic D, Alfirevic E. Miljan M. Transvaginal color Doppler for the assessment of pelvic circulation. Acta Obstet Gynecol Scand 1989:68:131-5.
113. Valentin L, Sladkevicius P, Marsal K. Limited contribution of Doppier velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 1994:83:425-33.
114. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994;83:434-7.
115. Carter JR, Lau M, Fowler JM, Carlson JW, Carson LR Twiggs LB. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172:901-7.
116. Bennecerraf B, Finkler N, Wejciechowski C, Knapp R. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med 1990:34:491-5.
117. VanNagell JR Jr, Depriest PD, GallianHH, Pavlik EJ. Ovarian cancer screening. Cancer 1993:71:1523.
118. Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan P, Collins WP Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991;43:92.
119. McGowan L, Lesher LR Norris HJ, et al. Misstaging of ovarian cancer. Obstet Gynecol 1985:65:568-72.
120. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983:250:3072-6.
121. Trimbos JB, Schueler JA, van der Burg M, et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991;67:597.
122. Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341.
123. Keettel WC, Pixley EE. Diagnostic value of peritoneal washings. Clin Obstet Gynecol 1958;1:592.
124. Rosenoff SH. Peritoneoscopy in the staging and followup of ovarian cancer. Semin Oncol 1975;2:223.
125. Buchsbaum HJ, Brady ME, Delgado P, et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989:169:226-32.
126. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 1990:322:1021-7.
127. Dembo AJ, Davy D, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990:75:263.
128. Sevelda P, Vavra N, Schmeper M, et al. Prognostic factors for survival in stage I epithelial ovarian cancer. Cancer 1990:65:2349-52.
129. Webb MJ, Decker DG, Mussey E, et al. Factors influencing survival in stage I ovarian cancer. Am J Obstet Gynecol 1973:116:222-8.
130. Purola E, Nieminen U. Does rupture of cystic carcinoma during operation influence the prognosis? Ann Chir Gynaecol Fenn 1968;57:615-7.
131. Kallioniemi OP, Punnonen R, Jattila J, et al. Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer 1988:61:334-9.
132. Gajewski WH, Fuller AF Jr, Pastel-Ley C, et al. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994;53:5-12.
133. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian cancer. Am J Obstet Gynecol 1993:169:40-52.
134. Pecorelli S, Bolis G, Colombo N, et al. Adjuvant therapy in early ovarian cancer [Abstract]. Proc Soc Gynecol Oncol 1994:A14.
135. Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 1991;43:203-5.
136. Fiver MS. Mallelano J. Hempling RE, et al. Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma. Gynecol Oncol 1990:39:249-52.
137. Pi vor MS, Malfetano J. Hakor TR. et al. Adjuvant cisplatin-based chemotherapy for slage I ovarian adenocarcinoma: a preliminary report. Gynecol Oncol 1989:35:69-72.
138. Fiver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for stage IC or stage 1 grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992:46:357-60.
139. Chiara S, Mammoliti S. Oliva G, et al. Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer. Eur J Cancer 1991:27:1211-5.
140. Rubin SC.WongGYC.Curtin [P. BarakatRR. Hakes TB, Hoskins WJ. Platinumbased chemotherapy of high-risk state I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993:82:143-7.
141. Wils J, van Geuns H. Chemotherapy consisting of cisplatin, doxorubicin, and oyclophosphamide as an adjunct to surgery in stage IC-II epithelial ovarian carcinoma. Am J Clin Oncol 1989:12:251-4.
142. Gadducci A, Del Bravo B, Cardosi Carrara A. el al. Adjuvant treatment of early stage ovarian cancer. Clin Exp Obstet Gynecol 1990:17:131-9.
143. Young RC, Brady ME Walter LA, et al. Localized ovarian cancer in the elderly. Cancer 1993:71:601-5.
144. Vergote IB. Winderen M. DeV'os LN. et al. Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Cancer 1993:71:2250-60.
145. Klassen D, Shelley W. Starrevele A, et al. Early slage ovarian cancer. | Clin Oncol 1988:6:1254-63.
146. Pezner RD, Stevens KR. Tong D, et al. Limited epithelial cancer of the ovary treated with curative intent by the intraperitoneal instillation of radiocolloids. Cancer 1978:42:2563-71.
147. Dembo AJ. Radiotherapeutic management ol ovarian cancer. Semin Oncol 1984:11:238-50.
148. Fuller DB, Sause WT, Plenk HF Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. I Clin Oncol 1987:5:897-905.
149. Goldberg N, Feschel R. Postoperative abdominopelvic radiation therapy for ovarian cancer, lut ) Radiât Oncol Biol Phvs 1988:14:425-9.
150. Weiser EB. Burke TW, Heller PB. Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation. Gynecol Oncol 1988:30:201-8.
151. Smith JP. Rutledge EN. Delclos L. Postoperative treatment of early cancer of the ovary: a randomized trial between postoperative irradiation and chemotherapy. Monogr Natl Cancer Inst 1975:42:149-53.
152. Sell A. Bertelson K, Andersen JE. Randomized study of whole abdomen irradiation versus pelvic irradialion plus cyclophosphamide in treatment of earh ovarian cancer. Gvnecol Oncol 1990:37:367-73.
153. Reinfuss M. Kojs Z. Skolyszewski J. External beam radiotherapy in the management of ovarian carcinoma. Radiother Oncol 1993:26:26-32.
154. Chiara S. Pierfranco C, Franzone P et al. High-risk early-stage ovarian cancer: randomized clinical trial comparing cisplalin plus cycluphosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 1994:17:72-6.
155. McGuire WSF Hoskins VYJ. Brady MF, et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1993:12.
156. Ozols KE Treatment of ovarian cancer: current status. Semin Oncol 1994:21(S2):1-9.